

 WELLMED Doctors helping patients for more than 25 years	Effective Date: 07/12/23	Revision Date(s):
Department: PHARMACY	MMC Review/ Approval Date(s): 01/15/19, 06/23/20, 11/08/22, 06/20/23	Total Page(s): 11
Policy Number: 061.000 Title: Coverage Determination Policy for Collagenase, Clostridium histolyticum (Xiaflex)		

Regions: <input checked="" type="checkbox"/> Texas <input type="checkbox"/> Florida <input type="checkbox"/> Indiana <input type="checkbox"/> New Jersey <input checked="" type="checkbox"/> New Mexico						
Impacted Areas: <table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top;"> <input checked="" type="checkbox"/> Network Management/Provider Services <input type="checkbox"/> Member services <input type="checkbox"/> Quality Management <input type="checkbox"/> Credentialing <input type="checkbox"/> IT <input type="checkbox"/> Administration <input type="checkbox"/> Compliance/delegation </td> <td style="width: 50%; vertical-align: top;"> <input checked="" type="checkbox"/> Utilization Management <input type="checkbox"/> Case management <input type="checkbox"/> Disease management <input checked="" type="checkbox"/> Claims <input type="checkbox"/> Human resources <input type="checkbox"/> Finance <input checked="" type="checkbox"/> Pharmacy <input type="checkbox"/> ALL </td> </tr> </table>					<input checked="" type="checkbox"/> Network Management/Provider Services <input type="checkbox"/> Member services <input type="checkbox"/> Quality Management <input type="checkbox"/> Credentialing <input type="checkbox"/> IT <input type="checkbox"/> Administration <input type="checkbox"/> Compliance/delegation	<input checked="" type="checkbox"/> Utilization Management <input type="checkbox"/> Case management <input type="checkbox"/> Disease management <input checked="" type="checkbox"/> Claims <input type="checkbox"/> Human resources <input type="checkbox"/> Finance <input checked="" type="checkbox"/> Pharmacy <input type="checkbox"/> ALL
<input checked="" type="checkbox"/> Network Management/Provider Services <input type="checkbox"/> Member services <input type="checkbox"/> Quality Management <input type="checkbox"/> Credentialing <input type="checkbox"/> IT <input type="checkbox"/> Administration <input type="checkbox"/> Compliance/delegation	<input checked="" type="checkbox"/> Utilization Management <input type="checkbox"/> Case management <input type="checkbox"/> Disease management <input checked="" type="checkbox"/> Claims <input type="checkbox"/> Human resources <input type="checkbox"/> Finance <input checked="" type="checkbox"/> Pharmacy <input type="checkbox"/> ALL					

Available LCD/NCD/LCA: None

Disclaimer:
 WellMed Coverage Determination Policies are developed as needed, are regularly reviewed and updated, and are subject to change. They represent a portion of the resources used to support WellMed coverage decision making. WellMed may modify these Policy Guidelines at any time. Medicare source materials used to develop these guidelines include, but are not limited to, CMS National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Medicare Benefit Policy Manual, Medicare Claims Processing Manual, Medicare Program Integrity Manual, Medicare Managed Care Manual, etc. The information presented in the WellMed Coverage Determination Policies is believed to be accurate and current as of the date of publication, and is provided on an "AS IS" basis. Where there is a conflict between this document and Medicare source materials, the Medicare source materials will apply.

Title: Coverage Determination Policy for Collagenase, Clostridium histolyticum (Xiaflex)

Table of Contents	Page	Coverage Policy Number: 061.000
Coverage Determination (Initial/New Requests)	3	Line of Business: Medicare Part B
Coverage Determination (Renewal/Continuation of Therapy Requests)	4	Policy Type: Prior Authorization
FDA Approved Dose and Indication	5	
General Background	6	
Clinical Evidence	7	
HCPCS Code	8	
Acronyms	9	
References	10	
Policy History/Revision Information	11	

Coverage Determination

(Initial/New Requests)

Collagenase, Clostridium histolyticum (Xiaflex) is medically necessary for the treatment of **Dupuytren's contracture** and **Peyronie's disease** when **ONE** the following criteria are met:

1. For **Dupuytren's contracture**, **ALL** of the following criteria must be met:
 - A. Diagnosis of Dupuytren's contracture with a palpable cord
 - B. Patient is 18 years of age or older
 - C. Patient has a documented contracture of at least 20 degrees flexion for a metacarpophalangeal joint or a proximal interphalangeal joint
 - D. Patient has a flexion deformity that results in functional limitations
 - E. Patient has not received surgical treatment on the selected primary joint within the last 90 days
 - F. If two injections (two vials) are requested, they are for **ONE** of the following:
 - I. One cord affecting two joints in the same finger
 - II. Two cords affecting two joints in the same hand
 - III. N/A
 - G. Dosing is in accordance with the United States Food and Drug Administration approved labeling
 - H. The total number of injections does not exceed 3 injections per cord at approximately 4-week intervals
 - I. Authorization is for no more than 2 injections in the same hand

2. For **Peyronie's disease**, **ALL** of the following criteria must be met:
 - A. Patient has a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy
 - B. Patient is 18 years of age or older
 - C. Patient does NOT have plaques that involve the penile urethra
 - D. Dosing is in accordance with the United States Food and Drug Administration approved labeling
 - E. Authorization is for no more than 2 injections

(Renewal/Continuation of Therapy Requests)

RENEWAL criteria for **Xiaflex**: **ONE** of the following must be met:

1. For **Dupuytren's contracture**, **ALL** of the following must be met:
 - A. Patient has previously received Xiaflex
 - B. Documentation of positive clinical response to Xiaflex
 - C. Treatment request is for at least **ONE** of the following:
 - I. Metacarpophalangeal (MP) or proximal interphalangeal (PIP) contracture remains in affected cord since previous injection and the contracture is > 5 degrees
 - II. A different MP or PIP contracture will be injected
 - D. If two injections (two vials) are requested, use is for **ONE** of the following:
 - III. One cord affecting two joints in the same finger
 - IV. Two cords affecting two joints in the same hand
 - V. N/A
 - E. Member has not received surgical treatment (e.g., fasciectomy, fasciotomy) on the selected primary joint within the last 90 days
 - F. The previous treatment was at least 4 weeks ago
 - G. Dosing is in accordance with the United States Food and Drug Administration approved labeling
 - H. The total number of injections does not exceed 3 injections per cord at approximately 4-week intervals
 - I. Authorization is for no more than 2 injections in the same hand

2. For **Peyronie's disease**, **ALL** of the following must be met:
 - A. Patient has previously received Xiaflex
 - B. Documentation of positive clinical response to Xiaflex
 - C. Last treatment was at least 6 weeks ago
 - D. Documented curvature deformity of ≥ 15 degrees remaining since last treatment cycle
 - E. Patient has received less than 4 treatment cycles (i.e. less than 8 injections [2 injections per cycle])
 - F. Dosing is in accordance with the United States Food and Drug Administration approved labeling
 - G. Authorization is for no more than 2 injections

FDA Approved Dose and Indication

FDA approved indications	Approved Dosing
<p>The treatment of adult patients with Dupuytren’s contracture with a palpable cord</p>	<p>Inject 0.58 mg of XIAFLEX intralesionally into each palpable Dupuytren’s cord, if contracture persists after 24 to 72 hours, perform a finger extension procedure to facilitate cord disruption; if contracture remains after 4 weeks, may reinject with a single dose of 0.58 mg INTRALESIONALLY followed by finger extension procedure 24 to 72 hours later; may perform up to 3 injection and finger extension procedures per cord at 4-week intervals; may perform 2 injections in same hand per visit</p>
<p>The treatment of adult men with Peyronie’s disease</p>	<p>Inject 0.58 mg Intralesionally for 2 injections separated by 1 to 3 days and perform a penile modeling procedure 1 to 3 days after the second injection; interval between treatment cycles is approximately 6 weeks; if after the first, second, or third treatment cycle, curvature deformity is less than 15 degrees or further treatment is not clinically indicated, subsequent treatment cycles should not be administered; MAX: 4 treatment cycles</p>

General Background

Xiaflex® (Collagenase, Clostridium histolyticum) is indicated for the treatment of adults with Dupuytren contracture with a palpable cord and for treatment of Peyronie disease in adult men with a palpable plaque and curvature deformity of at least 30 degrees at initiation of therapy. Clostridium histolyticum collagenase consists of 2 microbial collagenases (AUX-I and AUX-II) that synergistically hydrolyze collagen resulting in lysis of collagen deposits and may result in enzymatic disruption of the cord in patients with Dupuytren contracture and in the plaque associated with Peyronie disease.

Precautions and Warnings

Xiaflex - Black Box Warning

- Corporal rupture (penile fracture) or other serious penile injury may occur during xiaflex administration.

Clinical Evidence

Xiaflex® (Collagenase, Clostridium histolyticum)

Contractures were released to 0 to 5 degrees of full extension after 3 injections of collagenase clostridium histolyticum in 44% to 64% of patients with metacarpophalangeal (MP) or proximal interphalangeal (PIP) contractures, compared with 5% to 6.8% who received placebo, in 1 study (N=308). Contracture release was reached after just 1 injection in 27% to 39% of those receiving collagenase clostridium histolyticum compared with 1% to 5% placebo in another study (N=66). The probability of remaining recurrence-free at 5 years after successful treatment was about 50% in a long-term follow-up study (N=645). Retreatment using up to 3 injections in patients with recurrent contractures (N=52) was clinically successful in 65% of MP joints and in 45% of PIP joints.

Collagenase clostridium histolyticum was superior to placebo for the treatment of Peyronie disease in 2 multicenter, randomized, double-blind, controlled trials (n=832). Adult men with penile curvature deformity of a minimum of 30 degrees in a stable phase of Peyronie disease were eligible. Patients with ventral curvature deformity, isolated hourglass deformity, or a calcified plaque that may interfere with injection technique were excluded. At baseline, 98% of patients had no penile pain or mild penile pain. Patients were stratified by the baseline degree of curvature deformity (30 to 60 degrees; 61 to 90 degrees) and randomized in a 2:1 ratio to receive up to 4 treatment cycles of collagenase clostridium histolyticum or placebo. Each treatment cycle consisted of 2 study drug injections administered 1 to 3 days apart, followed by a penile modeling procedure 1 to 3 days after the second injection of the treatment cycle. Treatment cycles were repeated at approximately 6-week intervals for a maximum of 3 cycles (i.e., maximum 8 total injections and 4 total modeling procedures). Patients were advised to perform penile modeling procedures at home for 6 weeks after each treatment cycle.

HCPCS Code

HCPCS Code	Description
J0775	Xiaflex (Collagenase, Clostridium histolyticum) Injection, 0.01 mg

Acronyms

MP = Metacarpophalangeal

PIP = Proximal interphalangeal

References

1. Xiaflex In: DRUGDEX System. Micromedex® (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com/> (December 20, 2021)
2. Product Information: XIAFLEX(R) intralesional injection, collagenase clostridium histolyticum intralesional injection. Auxilium Pharmaceuticals, Inc. (per FDA), Malvern, PA, 2015.
3. Hurst LC, Badalamente MA, Hentz VR, et al: Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009; 361(10):968-979. PubMed Article: https://www.ncbi.nlm.nih.gov/pubmed?cmd=Link&dbFrom=PubMed&from_uid=19726771

